Donor Selection And Cell Source Summit The Clift Royal Sonesta San Francisco, San Francisco

As the allogeneic cell therapy space continues to mature with over 150+ clinical trials currently underway, and landmark milestones achieved with the first FDA approvals for allogeneic cell products – all eyes are turning to the backbones of these cell therapies – the cell donors. The field is awakening to the challenging reality of the increased demand for donor material to meet the required dosing needs for later stage clinical trials and licensed products.

Enter the timely arrival of the inaugural Donor Selection and Cell Source Summit, the pioneering forum for cell therapy leaders within process development, supply chain, procurement, R and D and analytics, placing a spotlight focus on cell source starting material for the first time.

With experts showcasing in-depth case studies of novel technology platforms and cell sources being utilized to increase yield, and new donor characteristic screening strategies to select for ‘gold-standard’ donors to achieve optimal clinical results for patients.

Speakers: Aaron Goldman – Instructor in Medicine | Director of Drug Resistance – Brigham and Women’s Hospital, Allen Feng – Founder | CSO – HebeCell, Amanda Conerty – Exec. Director Process, Analytical Development and Manufacturing – Artiva Biotherapeutics and More.